MedTrace Logo

Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients

NCT01507532 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-03-20

No results posted yet for this study

Summary

Ceftazidime is a broad spectrum cephalosporin with high activity against a variety of Gram-negative pathogens, including Pseudomonas aeruginosa. An open-label study of intravenous ceftazidime pharmacokinetics will be performed in patients undergoing intermittent hemodialysis at Northwestern Memorial Hospital to determine the clearance of ceftazidime in high flux hemodialysis.

Conditions

  • Renal Failure

Interventions

OTHER

pharmacokinetic monitoring

pharmacokinetic monitoring

Sponsors & Collaborators

  • Midwestern University

    lead OTHER

Principal Investigators

  • Marc H Scheetz, PharmD · Midwestern University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507532 on ClinicalTrials.gov